tiprankstipranks
INVO Fertility (IVF)
NASDAQ:IVF
US Market
Want to see IVF full AI Analyst Report?

INVO Fertility (IVF) AI Stock Analysis

280 Followers

Top Page

IVF

INVO Fertility

(NASDAQ:IVF)

Select Model
Select Model
Select Model
Neutral 46 (OpenAI - Gpt-5.6Sol)
Rating:46Neutral
Price Target:
$1.00
▲(0.00% Upside)
Action:Reiterated
Date:08/20/26
The score is primarily held back by persistent losses and ongoing cash burn, despite meaningful revenue growth and a notably improved balance sheet. Technicals show only early signs of stabilization within a broader downtrend, while valuation remains constrained by negative earnings. Corporate events are a modest positive, improving operational control and reducing listing/compliance risk.
Positive Factors
Strong Revenue Expansion
The substantial multi-year revenue increase indicates improving commercial traction for INVO’s fertility services and technology. Sustained growth can broaden the operating base and provide greater leverage for future margin improvement if expansion continues.
Negative Factors
Persistent Structural Losses
Despite meaningful revenue growth and positive gross margins, INVO has not demonstrated a clear path to operating profitability. Continuing losses limit internal funding capacity and leave results vulnerable if growth does not translate into scale efficiencies.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Expansion
The substantial multi-year revenue increase indicates improving commercial traction for INVO’s fertility services and technology. Sustained growth can broaden the operating base and provide greater leverage for future margin improvement if expansion continues.
Read all positive factors

INVO Fertility (IVF) vs. SPDR S&P 500 ETF (SPY)

INVO Fertility Business Overview & Revenue Model

Company Description
INVO Fertility, Inc. is a profitable enterprise primarily focused on delivering fertility services. Beyond this core business, the company actively develops clinical-stage therapies targeting oncology and autoimmune disorders. The firm was establi...
How the Company Makes Money
null...

INVO Fertility Financial Statement Overview

Summary
Strong multi-year revenue growth to ~$7.5M TTM and improved leverage (debt-to-equity ~0.27) are positives, but the business remains structurally unprofitable with deeply negative margins and sizable TTM net losses. Cash flow is the biggest drag, with negative operating cash flow and free cash flow (~-$4.8M TTM), keeping financing risk elevated.
Income Statement
22
Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue7.53M6.84M6.53M3.02M822.20K4.16M
Gross Profit2.51M2.53M2.87M1.09M-28.57K4.02M
EBITDA-6.10M-3.51M-7.14M-6.88M-10.75M-5.22M
Net Income-5.29M-23.32M-9.10M-8.03M-10.89M-6.65M
Balance Sheet
Total Assets25.83M20.22M46.45M18.51M3.71M10.47M
Cash, Cash Equivalents and Short-Term Investments3.73M2.08M741.40K232.42K90.14K5.68M
Total Debt3.92M3.40M9.90M6.30M2.27M2.12M
Total Liabilities9.34M13.00M33.70M17.61M4.69M3.16M
Stockholders Equity16.49M7.22M12.75M892.83K-977.61K7.31M
Cash Flow
Free Cash Flow-4.81M-7.06M-3.16M-5.20M-6.62M-6.48M
Operating Cash Flow-4.77M-7.01M-2.97M-4.76M-6.60M-6.03M
Investing Cash Flow-2.93M-2.75M363.89K-2.49M-81.22K-2.15M
Financing Cash Flow10.88M11.10M3.12M7.39M1.09M3.77M

INVO Fertility Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.00
Price Trends
50DMA
1.25
Negative
100DMA
1.56
Negative
200DMA
4.49
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
46.60
Neutral
STOCH
8.63
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IVF, the sentiment is Negative. The current price of 1 is below the 20-day moving average (MA) of 1.06, below the 50-day MA of 1.25, and below the 200-day MA of 4.49, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.60 is Neutral, neither overbought nor oversold. The STOCH value of 8.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IVF.

INVO Fertility Risk Analysis

INVO Fertility disclosed 60 risk factors in its most recent earnings report. INVO Fertility reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

INVO Fertility Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
46
Neutral
$2.66M-0.57-471.55%13.76%99.18%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IVF
INVO Fertility
1.06
-43.74
-97.63%
NIVF
NewGenIvf Group
0.58
-323.42
-99.82%

INVO Fertility Corporate Events

Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and ComplianceShareholder Meetings
INVO Fertility Expands Authorized Shares to Support Financing
Neutral
Jul 24, 2026
On January 23, 2026, INVO Fertility held its annual meeting of stockholders, where shareholders re-elected all five directors and ratified Withum Smith+Brown, PC as the company’s independent auditor for the 2026 fiscal year. Investors also a...
Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsRegulatory Filings and Compliance
INVO Fertility Gains Full Control of Alabama Clinic
Positive
Jun 25, 2026
On June 23, 2026, INVO Fertility’s subsidiary INVO Centers acquired 100% of the membership interests in HRCFG, its joint venture partner in the Birmingham, Alabama fertility clinic, for a total consideration of $175,001 structured with minim...
Business Operations and StrategyRegulatory Filings and Compliance
INVO Fertility Updates Investors With New Presentation
Neutral
Jun 16, 2026
On June 16, 2026, INVO Fertility posted a new investor presentation on its website ahead of its appearance at the Planet MicroCap Conference scheduled for June 17, 2026. The presentation outlines the company’s current and long-term operation...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 20, 2026